Veeva Systems and Sarah Cannon Research Institute Unite to Enhance Clinical Oncology Studies

Enhancing Clinical Oncology Research

In a groundbreaking initiative, Veeva Systems (NYSE: VEEV) has joined forces with the esteemed Sarah Cannon Research Institute (SCRI) to significantly accelerate the pace and efficiency of clinical oncology studies. Announced on June 4, 2025, this strategic collaboration aims to integrate advanced technology solutions throughout SCRI's extensive network of over 200 research sites.

With the adoption of the Veeva Clinical Platform, SCRI is set to revolutionize its operations. This unified platform will merge the duties of their Contract Research Organization (CRO) and Site Management Organization (SMO), ensuring seamless data flow between clinical teams and research sites.

The Chief Information and Digital Officer of SCRI, Yazhene Krishnaraj, expressed enthusiastic support for this integration, stating, "We are thrilled to enhance our clinical studies by incorporating the Veeva Clinical Platform into our digital toolkit. This collaboration will empower our clinical teams to deliver cutting-edge therapies to patients with greater precision and speed."

One of the primary goals of this partnership is to simplify and standardize study processes and information flow. By fostering collaboration between investigators and clinical teams, SCRI will improve data exchange and enhance the overall trial experience. This connected foundation is anticipated to automate key processes, leading to a more optimized environment for research sites.

Jim Reilly, President of Veeva Development Cloud, emphasized the importance of this collaboration in the following terms: "We are excited to partner closely with SCRI to drive advancements in oncology research. Veeva Clinical Platform will serve as the backbone for SCRI's clinical studies, enhancing efficiencies through standardized procedures on a single platform. This will enable quicker and more cost-effective studies."

What is Veeva Clinical Platform?

The Veeva Clinical Platform presents an all-encompassing, connected solution for clinical operations and data applications. This end-to-end system encompasses multiple functionalities, including Clinical Trial Management System (CTMS), Electronic Data Capture (EDC), Clinical Workbench (CDB), Randomization and Trial Supply Management (RTSM), electronic Clinical Outcome Assessments (eCOA), electronic Trial Master Files (eTMF), Site Connect, Study Training, and more.

The platform’s interconnected products streamline clinical trials from initiation to completion, facilitating an automated data flow that enhances efficiency and accuracy. For further information on the advancements offered by the Veeva Clinical Platform, interested parties can visit veeva.com/eu/VeevaClinicalPlatform.

About Sarah Cannon Research Institute

The Sarah Cannon Research Institute stands as a leader in oncology research, specializing in community-based clinical trials. Over the past three decades, SCRI has committed itself to developing therapies for patients and has been instrumental in drug development. To date, the institute has conducted more than 850 clinical first-in-human trials and contributed to pivotal research that led to the most novel cancer therapies approved by the FDA in the last decade.

The SCRI research network boasts over 1,300 physicians at more than 200 sites across 20 states, actively enrolling patients for clinical trials. For more detailed insights about SCRI's comprehensive research efforts, please visit SCRI.com.

About Veeva Systems

Veeva is the preeminent provider of cloud software tailored for the life sciences industry. With a commitment to innovation and product quality, Veeva supports over 1,000 clients ranging from leading biopharmaceutical companies to emerging biotech firms. As a Public Benefit Corporation, Veeva balances the interests of various stakeholders, including clients, employees, shareholders, and the industries it serves. More information can be found at veeva.com/eu.

This partnership between Veeva Systems and Sarah Cannon Research Institute is set to redefine the pace and quality of clinical oncology studies, ultimately leading to better patient outcomes through enhanced research efficiency.